The latest price target for BioXcel Therapeutics (NASDAQ:BTAI) was reported by HC Wainwright & Co. on September 6, 2024. The analyst firm set a price target for $7.00 expecting BTAI to rise to within 12 months (a possible 1114.01% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for BioXcel Therapeutics (NASDAQ:BTAI) was provided by HC Wainwright & Co., and BioXcel Therapeutics reiterated their buy rating.

The last upgrade for BioXcel Therapeutics Inc happened on December 1, 2022 when Goldman Sachs raised their price target to $16. Goldman Sachs previously had a sell for BioXcel Therapeutics Inc.

The last downgrade for BioXcel Therapeutics Inc happened on February 21, 2024 when UBS changed their price target from $9 to $4 for BioXcel Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioXcel Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioXcel Therapeutics was filed on September 6, 2024 so you should expect the next rating to be made available sometime around September 6, 2025.

While ratings are subjective and will change, the latest BioXcel Therapeutics (BTAI) rating was a reiterated with a price target of $7.00 to $7.00. The current price BioXcel Therapeutics (BTAI) is trading at is $0.58, which is out of the analyst’s predicted range.